Search

This study was carried out to examine the relationship between perfectionism, which is a personality trait, and work-family conflict. Also, within the scope of the study, the differences between the demographic characteristics of the participants and their perfectionism attitudes and the work-family conflict were tried to be determined. The sample of the study consists of 203 nurses working in the public sector. The analyzes revealed that there was a significant difference between the perfectionism attitudes of the participants and their levels of work-family and family-work conflict. Accordingly, participants with high maladaptive perfectionism scores experience more work-family conflicts than those who are adaptive perfectionists and non-perfectionists. The analyzes also showed that participants with a tendency to perfection experience higher levels of family-work conflict. Finally, significant differences were found between the perfectionism attitudes of the participants and the administrative task, gender and work-family conflict, the variables of administrative duty and number of children and family-work conflict. Findings obtained within the scope of the research are discussed in the context of the literature.

Women are an important part of today's business life. Nevertheless, research shows that gender discrimination is a frequently encountered problem in working life. These findings, however, focus on gender discrimination within the enterprise. In other words, gender discrimination practices that may exist during recruitment and placement before employment are relatively neglected in the literature. The aim of the study, in the framework of the ads and civil engineering context of Turkey, is to reveal whether there is gender discrimination in the job advertisements, which is the first stage of the recruitment process. Within the scope of the study, 112 civil engineering advertisement published on www.kariyer.net between 01-31 January 2019 has been examined by using content analysis method. Analysis shows that almost all of the job advertisements contain masculine / feminine expressions. Accordingly, it has been etermined that the job advertisements examined are generally shaped by taking into consideration the masculine qualities in a way that will give advantage to male candidates. As a result of the study, it was concluded that direct and indirect gender discrimination was made in the job advertisements examined., Kadınlar günümüz çalışma yaşamının önemli bir parçasıdır. Buna rağmenyapılan araştırmalar çalışma yaşamında cinsiyet ayrımcılığının sıklıklakarşılaşılan bir sorun olduğunu göstermektedir. Ancak elde edilen bu bulgularişletme içinde yaşanan cinsiyet ayrımcılığına odaklanmaktadır. Bir diğerifadeyle işe girmeden önce işe alma ve yerleştirme aşamasında var olabilecekcinsiyet ayrımcılığı uygulamaları literatürde görece ihmal edilmiş bir konudur.Buradan hareketle bu çalışmanın amacı, Türkiye bağlamında ve inşaatmühendisliği ilanları çerçevesinde işe alım sürecinin ilk aşamasını oluşturaniş ilanlarında cinsiyet ayrımcılığı yapılıp yapılmadığını ortaya koymaktır.Çalışma kapsamında 01-31 Ocak 2019 tarihleri arasında www.kariyer.net sitesinde yayınlanan112 inşaat mühendisliği ilanı içerik analizi yöntemi kullanılarakincelenmiştir. Yapılan analizler iş ilanlarının neredeyse tamamına yakınıneril/dişil ifadeler içerdiğini göstermiştir. Buna göre incelenen iş ilanlarınıngenel olarak erkek adaylara avantaj sağlayacak şekilde eril niteliklergözetilerek şekillendirildiği tespit edilmiştir. Çalışma sonucunda incelenen iş ilanlarındadoğrudan ve dolaylı cinsiyet ayrımcılığı yapıldığı sonucuna ulaşılmıştır.

Background:Several factors such as effectiveness, safety and compliance affect the drug survival in chronic disorders. Physicians take care of long-term retention rate and responses for discontinuation of candidate drug. Identification of predictors of clinical response to certolizumab-pegol (CZP) may aid the decision-making process for treating patients psoriatic arthritis (PsA).Objectives:The purpose of this study to assess the drug survival of certolizumab pegol (CZP) in patients with PsA and to identify the predictors and reasons for discontinuation.Methods:Data on patient characteristics, demographics, diagnosis, disease duration, treatment and outcomes have been collected since 2011 in Turkish Biologic (TURKBIO) Registry. By the end of December 2020, 68 PsA patients received CZP and were included. Kaplan Meier plot was used for drug survival analysis. Cox regression analysis was performed to evaluate the predictors associated with drug survival.Results:During the median 47 months follow-up, 17 patients discontinued the CZP treatment. The reasons for discontinuation were ineffectivity (35.3%), adverse event (17.6%) and pregnancy (5.9%). The baseline characteristics of the patients who continued and discontinued CZP were shown in the Table 1. Patients who discontinued CZP had higher mean age and disease duration. HLA-B27 positive patients had lower retention rate while bDMARD naive patients had higher retention rate. At the month 36, retention rate of CZP was 61.6% on patients with PsA (Figure 1).Conclusion:Real life experience from this nationwide TURKBIO registry show that the retention rate of CZP in PsA are lower in older patients and with longer disease duration. Moreover, bDMARD naive patients have higher retention rate.Figure 1.Drug survival of CZP in patients with PsATable 1.Baseline characteristics of PsA patients who continue and discontinue CZPAll Patients (n=68)Continue to CZP (n=51)Discontinue to CZP (n=17)pFemales, n (%)52 (76,5)37 (72,5)15 (88,2)0,322Age, years44 (36-57)40 (35-53)51 (42-60)0,012Disease Duration, years9 (5-13)8 (5-12)14 (10,5-17)0,002Symptom duration, years11 (7-16)10 (7-15)15,5 (11,5-20)0,014Order of CZP in bDMARDs1 (1-2)1 (1-2)2 (1-2)0,062HLA-B27, n (%)9 (28,1)3 (14,3)6 (54,5)0,035ESR, mm/h23,5 (11-37)23 (9-35)24 (17-52)0,246Swollen Joint Counts, n0 (0-2)0 (0-2)1 (0-2)0,480Tender Joint Counts, n2 (0-4)1 (0-4)2 (1-5)0,143CRP, mg/dl4 (3-13,65)3,14 (3-13)5 (3-19)0,107HAQ0,63 (0,25-1)0,63 (0,25-1)0,75 (0,63-0,94)0,097VAS-Physicians20 (12-31,5)20 (12-26)30 (15-50)0,074VAS-Patient Global50 (27-70)50 (20-70)61,5 (46,5-70)0,342VAS-Patient Pain53 (28-75)50 (20-75)69 (49,5-75)0,122DAS-28-CRP3,35 (2,2-3,9)2,85 (2-3,8)3,6 (2,9-4,4)0,086BASFI15 (8-27)14 (5-26)23,5 (12-30,5)0,133BASDAI28 (16-40)27,5 (14-36)39 (22,5-41,5)0,060ASDAS2,7 (1,9-3,2)2,6 (1,9-3,1)3 (2,35-3,4)0,122DAPSA-2815,35 (7,2-21,9)14,9 (6,1-21,17)18,9 (14,15-29,3)0,108Disclosure of Interests:None declared.

Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints and spine as well as peripheral joints and entheses. Tumour necrosis factor inhibitors (TNFi) are widely used in patients with persistently high disease activity despite non-steroidal anti-inflammatory drugs. Some patients fail to respond or loose responsiveness during therapy with TNFi. The development of anti-drug antibodies (ADA) might play a role in non-response or some adverse events. However it has never been evaluated for 2-years period.Objectives:Therefore, the aim of the present study was to evaluate the development of ADA against TNFi longitudinally during 2-years period in axSpA patients and factors associated with it.Methods:In total 180 axSpA patients according to ASAS classification criteria with a new TNFi prescription in the last two weeks period were included in this observational study. Clinical data and serum samples were collected at baseline and at every 12 weeks. Serum drug levels and ADAs were measured on 12, 24, 52 and 104 weeks of treatment by ELISA in one center to avoid inter-assay variability. The development of ADA over time was investigated by using generalized estimating equations (GEE) which is a technique for longitudinal data analysis allowing the use of all available data even deviated from normality.Results:180 biologic naive axSpA patients (116 male, median [IQR] 44,5 [14,5] years) who started anti-TNF agents (infliximab [20%], adalimumab [27,2%], etanercept [32,2%] and golimumab [20,6%]) were included in the analysis. In comparison to baseline values BASDAI, ASDAS-CRP and CRP values were significantly decreased in third months of follow-up (Figure 1). In total 172 patients had at 12 weeks, 154 at 24, 121 at 52, and 73 at 104 week serum samples available for ADA determination. In longitudinal analysis; baseline age and TNFi type, as well as longitudinal BASDAI, ASDAS, serum CRP levels and the development of adverse events and discontinuation of the drug were found to be associated with the development of ADA. In order to determine independent association/s with the development of ADA two longitudinal multivariable models were run; (a) with ASDAS as an activity measure, (b) with BASDAI and CRP levels and produced that all the variables were independently associated with longitudinally development of anti-drug antibodies (Table 1). Antibodies to adalimumab were related with lower serum drug levels.Conclusion:The results of the present study with up to 2 years of follow-up, revealed that the development of ADA against TNFi therapy is associated with high disease activity, the development of adverse events and treatment discontinuation in patients with axSpA. And etanercept might be negatively associated with the development of ADA.Table 1.Factors associated with the development of anti-drug antibodiesModel 1Model 2B95% CIPB95% CIPAge years-0.061-0.109;-0.0120.015-0.058-0.107;-0.0100.018TNFi Treatment ETN-1.981-4.369; -0.1340.104-2.475-4.791; -0.0760.036 ADA1.438-0.002; 0.4070.0731.275-0.119; -0.1600.064 INF1.5503.010; 3.1020.0501.2552.666; 2.6290.073 GOL0a0aPresence of advers event, no-0.824-1.451; -.01980.010-0.835-1.461; -0.2080.009TNF treatment discontinuation1.2890.043;2.5340.0431.248-0.075; 2.5710.065BASDAI0.0350.015; 0.0550.001CRP0.020-0.035; 0.0050.008ASDAS-CRP0.8520.466; 1.2380.0000a:set to zero because this parameter is redundant.Figure 1.Mean change in disease activity and CRP levels during follow-up duration. (P values for 3rd months BASDAIDisclosure of Interests:None declared

Background:Although psoriatic arthritis (PsA) may be seen at any decades, juvenil onset PsA is relatively rare. Moreover, there were no more data about clinical features, treatments, and course in juvenile PsA when they reached to adult age.Objectives:The objective of this study was to assess and compare demographic and clinical features for juvenile onset PsA and adult onset PsA.Methods:PsART-ID is a multicenter, international database, investigating the disease characteristic in real life (1). Briefly, demographic data, PsA subtypes, uveitis, enthesitis, dactylitis, Co-morbidities, disease activity scores (TJC, SJC, VAS-pain, VAS patients and physician global assessments, VAS-fatigue, BASDAI), and functional status (HAQ-DI, BASFI) were recorded. Psoriasis and PsA starting age were noted, as well. Patients were classified as juvenile PsA or juvenile PsO (under 18 years old). Results were compared regarding to juvenile versus adult onset age.Results:Overall, 1644 PsA patients were included to study, 301/1644 (18.3%) patients had juvenile onset psoriasis. Of 39/1644 (2.4%) patients had juvenile onset PsA, as well. As expected, juvenile onset PsA patients were younger, however PsA disease duration were longer than adult onset PsA patients. There were no any difference between demographic and clinical data, except BMI and enthesitis were less frequently at the juvenile onset PsA groups. Although, ever csDMARD using were similar between two groups, however, juvenile onset PsA patients were used more frequently bDMARDs.Table.Comparison of demographic and clinical characteristics of juvenile and adult-onset psoriatic arthritisJuvenile onsetAdult onsetpN (%)39 (2.4)1605 (97.6)Female Sex n (%)24 (61.5)1006 (62.7)0.884PsA beginning age mean (SD)13.3 ± 3.8542.3 ± 12.9Current age mean (SD)26.6 ±10.747.3 ±13.07Duration of psoriasis (years)17.10 ± 11.2614.75 ± 11.780.124Duration of psoriatic arthritis (years)13.5 ±115.06 ± 6.7Cigarette smoking (ever) n (%)15/38641/14940.72Education duration/year (mean,SD)10.09 ± 3.679.52 ± 4.810.464BMI (kg/m2) (mean, SD)24.5 ±5.128.3 ± 5.21Family history of PsO/PsA n (%)15 (38.5)559 (34.9)0.642Nail involvement n (%)18 (46.2)762 (47.5)0.864Dactilitis n (%)9 (23.7)367 (24)0.958Entesitis n (%)3 (7.9)384 (25.7)0.013Uveitis n (%)-13 (4.3)0.713Axial involvement (%)15 (38.5)464 (29)0.199Methotrexate36 (92.3)1348 (84)0.162Sulfasalazine17 (43.6)612 (38.1)0.488Leflunomide14 (35.9)379 (23.6)0.076Biologic DMARDs102 (33.9)358 (26.8)0.013Conclusion:Although psoriasis may be seen frequently in the juvenile age, juvenile onset PsA was not so frequent in our PsA cohort. Although, ever csDMARD using were similar between two groups, however, juvenile onset PsA patients were used bDMARDs more frequently.References:[1]Kalyoncu U et al. The Psoriatic Arthritis Registry of Turkey: results of a multicenter registry on 1081 patients. Rheumatology. 2017;56:279-286.Disclosure of Interests:Serpil ERGULU EŞMEN: None declared, Ozun Bayindir: None declared, esen kasapoğlu: None declared, Sibel Bakirci: None declared, Dilek Solmaz: None declared, Gezmiş Kimyon: None declared, Atalay Doğru: None declared, Ediz Dalkiliç: None declared, Cem Özişler: None declared, Meryem Can: None declared, Servet Akar: None declared, Emine Figen Tarhan: None declared, Sule Yavuz: None declared, Levent Kiliç: None declared, Orhan Küçükşahin: None declared, Ahmet Omma: None declared, Emel Gönüllü: None declared, Fatih Yildiz: None declared, Duygu Ersözlü: None declared, abdurrahman tufan: None declared, Muhammet Çinar: None declared, Abdulsamet Erden: None declared, Sema Yilmaz: None declared, Seval Pehlevan: None declared, Mehmet Tuncay Duruöz: None declared, Sibel Aydin: None declared, Umut Kalyoncu Consultant of: Abbvie, Amgen, Janssen, Lilly, Novartis, UCB

Background:Rheumatoid arthritis(RA) is one of the most frequent rheumatic disease, and the age of onset is between 30-50 years old. Late-onset RA(LORA) is usually defined as RA with onset at age 60 or over.Objectives:To investigate the choice, effectiveness and the retention rate of biological drugs in LORA patients.Methods:TURKBIO registry is the Turkish version of Danish DANBIO rheumatological database which has been established in 2011. We studied RA patients in TURKBIO registry cohort between the dates of 2011 and 2020. All patients fulfilled the American College of Rheumatology criteria for RA and were classified into two groups based on their age at symptom onset: adult-onset RA(>18-Results:From 10 centers, 2111 RA patients recruited, and 8.8% of them was LORA patients. In LORA, the frequency of female was less than AORA. While, there was no difference between LORA and AORA in terms of erosion presence and RF positivity, antiCCP positivity was more frequent in LORA group. The use of antiTNF was lower, and the use of rituximab was more frequent in LORA. At 12 months after bDMARDs therapy, serum CRP and ESR levels and DAS28-CRP showed higher changes compared to baseline values in LORA. Although the mortality rate was higher in LORA, the adverse reactions were reported to be higher in AORA, and most common advers reaction was infections in both groups(Table). The longest survival was observed in infliximab and rituximab(median 22 and 20months) in LORA, in rituximab and golimumab(median 16 and 12months) in AORA.Conclusion:The frequency of LORA who uses bDMARDs was 8.8% in our database. In the elderly patient population, there are some reservations about the use of biological drugs in general due to several co-morbidities and concommitant drug used. Although data on this issue are limited, appropriate biological use can be effective and reliable in required patients.References:[1]Zulfigar AA, Niazi R, Pennaforte JL, Andres E. Late-onset rheumatoid arthritis: clinical, biyological, and therapeutic features about a retrospecttive study. Geriatr Psychol Neuropsychiatr Viell 2019;17:51-62Table.Comparison of demographic, laboratory findings and biological treatment(median;25-75)n(%)AORA ((n:1925)LORA (≥60)(n:186)pAge (year)54 (43-61)71 (68-74)Disease duration (year)11.4 (7-18)6 (4-9)Gender (Female)1562 (81)124 (67)Anti-CCP positivity747 (62)65 (72)0.044RF positivity721 (61)63 (70)0.085Erosion presence486 (56)41 (62)0.955Drug survival (months)18 (6-44)18 (4-31)0.046Concomitant csDMARDsMTX629 (34)39 (22)0.001SZP146 (8)13 (7)0.781LEF501 (27)35 (20)0.032bDMARDsAntiTNF1068 (56)73 (39)TCZ304 (16)20 (11)0,069TOFA294 (15)27 (15)0,784RTX439 (23)57 (31)0,016ABA298 (16)34 (18)0,317Response ΔESH-6 (-21-4)-18 (-36--3)0.016(12 months) ΔCRP-2 (-12-0.6)-9.3 (-28--0.1)0.014ΔDAS28-CRP-1.3 (-3--0.1)-2.2 (-3--1)0.023ΔHAQ-0.3 (-0.8-0)-0.4 (-0.8--0.1)0.114Adverse effects440 (23)32 (17)0.077Malignancy9 (0,5)3 (1.6)0.082Infection192 (10)10 (5)0.042Allergy63 (3)4 (2)0.404Dermatitis62 (3)1 (0,5)0.040Death18 (0.9)7 (4)0.004Other136 (7)11 (6)0.556Acknowledgments :NoneDisclosure of Interests: :None declared

Background Psoriatic arthritis (PsA) has a genetic background, approximately 40% of patients having a family history of psoriasis or PsA in first-degree relatives, which may impact the disease features. Objectives The aim of this study was to evaluate the effects of family history of psoriasis or PsA on the disease phenotypes. Methods The demographic and clinical data were retrieved from the longitudinal, multicenter PsArt-ID (Psoriatic Arthritis-International Database). Family history of psoriasis and PsA were investigated for 1st and 2nd degree relatives separately. The effect of the family history of psoriasis and/or PsA on disease phenotypes and severity were analysed, calculating the relative risks (RR). Results 1393 patients had the data for family history, 444 (31.9%) of whom was positive for psoriasis and/or PsA. The majority of the family history was only psoriasis (333/444; 75%) and 58.5% (260/444) of the patients had first-degree relatives affected. There was no differences in maternal or parental transmission rates however women had more psoriasis and/or PsA in their family (67.3% vs 32.7% p: 0.028). Patients with a family history had an earlier onset of age for psoriasis (29±14.8 vs 31±14.9 p: 0.007), more frequent nail involvement (50.7% vs 29.6% p: 0.032), more frequent enthesitis (28.2% vs 17.7% p Conclusions The family history of psoriasis and PsA has impacts on skin phenotypes, musculoskeletal features and the disease severity. The differences between family history of psoriasis and PsA and pustular vs plaque phenotypes may point out to a different genetic background and pathogenic mechanisms in these subsets. Disclosure of Interest None declared

Background The environmental and genetic factors play a crucial role in the pathogenesis of psoriatic arthritis (PsA) which may cause a difference in disease characteristics for patients from different geographical regions. Objectives The aim of the study was to explore the disease characteristics, treatment choices and comorbidities in patients with PsA in different countries to see the impact of geographic factors. Methods PsArt-ID (Psoriatic Arthritis- International Database) is a prospective, multicentre registry in PsA, which was initially developed in Turkey in 2014, with participation of Canada since 2015 and Italy since 2017. Patients with PsA are consecutively registered to this registry with the aim of investigating the real-life data. Patient characteristics across Turkey (n=1283) and Canada (n=119) are compared for this analysis. Results Canadian patients were older at the time of recruitment (Table). They also were more frequently smokers, had higher duration of education and higher BMI than patients in Turkey. Patients in Canada had more frequent polyarthritis (66.7% vs 39.6%, p Conclusions Geographical differences have impacts on the disease features in PsA, which may be due to genetic, environmental and cultural differences. The treatments are comparable suggesting a similar approach by the physicians. Disclosure of Interest None declared

Kadinlar gunumuz .rgutlerinin ayrilmaz birer parcasidirlar. Nitekim kadinlarin isletmeler icindeki sayilarinin ve gu.lerinin her gecen gun artmaya devam ettigi bir gercektir. Buna ragmen yapilan arastirmalar orgutsel baglamda kadinlari erkekler karsisinda dezavantajli durumda birakan politika, uygulama ve yapilanmalarin halen devam ettigini gostermektedir. Buradan hareketle bu calisma, isletme amaclari ve degerlerini sekillendiren isletme stratejilerinin olusturulmasinda cinsiyetin rolune iliskin bir bakis acisi sunmayi amaclamaktadir. Soz konusu amac cercevesinde bu calismada Turkiye’de faaliyet gosteren buyuk isletmelerin vizyon ve misyon bildirilerinde “eril” ve “disil” ifadelere ne duzeyde yer verildigi arastirilmistir. Arastirmanin amaci dogrultusunda 2014 yili itibariyla Fortune 500 Turkiye Listesi’nde yer alan 150 isletmenin vizyon ve misyon bildirileri icerik analizi yontemi ile incelenmistir. Arastirma sonucunda incelen vizyon ve misyon ifadelerinde eril bir soylemin varligi ortaya konmustur. Ulasilan bu bulgu literaturde konuya iliskin suregelen tartismalari destekler niteliktedir.

This study was designed with an aim to search for an answer to the question what is the current situation of the studies conducted on business ethics in the business management literature in Turkey. Within the scope of the study, 81 postgraduate theses prepared in the field of business management were examined in terms of methodology. In the analysis, it was seen that the majority of the theses were quantitative studies using the survey method as the data acquisition method. As a result of the analyses performed, it was detected that the theses on business ethics in Turkey shaped under the domination of positivist paradigm methodologically. However, most of the postgraduate theses were carried out in a superficial context, neglecting the requirements of positivist paradigm. In line with the findings obtained, it was concluded that the majority of the postgraduate theses on business ethics in Turkey were superficial studies ignoring the complicated nature of business ethics.&nbsp

Background Comorbidities are frequent in Psoriatic arthritis (PsA) and can have an impact on morbidity and mortality. Objectives We aimed to investigate the frequency of different comorbidities in PsA, how comorbidities have an impact on PsA features and which factors were associated with the occurrence of comorbidities in a large number of patients, using PsART (Psoriatic Arthritis Registry of Turkey)registry. Methods PsART is a national, web-based registry where consecutive patients with PsA are recruited and demographic, clinical and therapeutic information are collected as well as comorbidities. The following comorbidities are questioned: Hypertension (HT), hyperlipidemia, depression, diabetes mellitus (DM), hyperuricemia, coronary arterial disease, liver disease, cerebrovascular accident, cancer, and depression. BMI more than 30 is recorded as obesity. Patients with or without comorbidities were compared for their demographic features and outcome tools. Results One thousand and sixty-nine patients whom comorbidity data were available were analyzed. Within these 693 (64.8%) were women. Mean (SD) age was 46.9 (12.8), with a median (range) PsA duration 45 (0–545) months. The number of patients with 1, 2 and 3 comorbidities were 642 (60.1%), 345 (32.3%), and was 191 (17.9%), respectively. Frequency of comorbidities was obesity in 327 (30.6%), HT in 256 (23.9%), hyperlipidemia in 199 (18.6%), depression in 188 (17.6%), DM in 161 (15.1%), hyperuricemia in 74 (6.9%), coronary artery disease in 39 (3.6%), liver disease 38 (3.6%), cerebrovascular event in 19 (1.8%), and cancer history 16 (1.5%). Patients with at least one comorbidity were older (51.1 (11.8) vs 40.9 (11.7), p Conclusions Our registry supported that comorbidities are frequent in PsA increasing the complexity of the disease and have an impact on the disease severity. Patients with comorbidities are less educated showing that education and awareness are important to improve patient outcomes in PsA in long term. Disclosure of Interest None declared

This study was conducted to investigate the effect of organizational silence on job satisfaction of employees. Besides, in the scope of this study, differences between demographic characteristics of the participants and, organizational silence and job satisfaction level were also examined. In line with the aim of this research, data were obtained from 138 bank employees in Ankara and Çankırı province. Based on the results of the analysis, it has been determined that organizational silence weakly impacts the job satisfaction in negative direction. At the same time, significant correlations has been identified between the participants' age, marital status, title variables and lack of experience which is sub-dimension of organizational silence. It is determined that the job satisfaction level of participants vary according to marital status and the title variable. The obtained results are discussed in the context of the stated meanings for researchers and practitioners.

Strong ethical climate at all levels is a necessity for any community to function in a healthy matter. This requirement has a far greater importance for the business world because it creates a favorable ground for ethics violations. In this context, in what extent ethical principles find a place in the business strategies of the company and the market is a question to be answered. Thus, with the thought to provide a perspective on the role of ethics in business strategy, large enterprises operating in Turkey have been investigated about how much ethical statements are used in the vision and mission expressions in this study. For the purpose of the research, vision and mission statements of top 100 companies in Fortune 500 Turkey List that announced on 2014 Fortune Turkey magazine have been investigated by using the content analysis method. The findings were discussed in the framework of the research objectives.

Kadınlargünümüz örgütlerinde her geçen gün daha da artan oranlarda yer bulmaktadırlar.Bununla birlikte hem örgütlerin hem de yönetim ve organizasyon yazınınınesasında cinsiyet körü bir yapıya sahip olmakla eleştirildiği görülmektedir. Bueleştirilerin en güçlüsü ise feminist teoriden gelmektedir. Bu bağlamdabetimsel bir nitelik taşıyan bu çalışmada yönetim ve organizasyon alanında varolduğu iddia edilen cinsiyet temelli bu yapılanmanın izini sürmekamaçlanmaktadır. Yapılan tartışmalar sonucunda feminist teorinin görmezdengelinen bir konu olan cinsiyet konusunu tartışmaya açarak yönetim veorganizasyon alanına önemli katkıları olduğu kanısına ulaşılmıştır.&nbsp

Objectives To evaluate the diagnostic and discriminative ability of the new 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) polymyalgia rheumatica (PMR) classification criteria compared to previous five diagnostic/classification criteria for PMR in a multi-centre prospective study. Methods Patients older than 50 years of age (n=163), presenting with new onset (symptom duration ≤24 weeks) bilateral shoulder pain with elevated acute phase reactants were enrolled from 15 rheumatology clinics in Turkey. Patients were prospectively followed and the diagnosis of PMR was established when the diagnosis was maintained without an alternative diagnosis at 6 months of follow-up. Those who were diagnosed as other than PMR at the 6th month were designated as control group. All patients were classified by each of the six different criteria for PMR and 2010 ACR/EULAR Rheumatoid arthritis (RA) classification criteria. Results Of the 163 patients with new-onset (mean symptom duration 10.9±7.5 weeks) bilateral shoulder pain 92 (56.4%) patients were diagnosed as PMR and 71 (43.6%) were diagnosed as nonPMR (RA: n=26). The discriminative ability as estimated by the area under the receiver operating characteristic (ROC) curve, was better for the Chuang criteria (0.83) than 2012 EULAR/ACR clinical criteria for PMR (0.69), Jones (0.68), Bird (0.68) and Nobunaga (0.77) criteria (Table 1). The 2012 EULAR/ACR clinical criteria for PMR had a sensitivity of 90.2% and a specificity of 49.3%. Jones and Chuang criteria had the highest specificity (91.5 and 87.3%, respectively). The specificity of the new 2012 EULAR/ACR clinical criteria for PMR slightly increased to 53.8% in RA patients. Although the new 2010 ACR/EULAR RA classification criteria classified only 9 out of 92 PMR patients as RA, the new 2012 EULAR/ACR clinical criteria for PMR classified 12 out of 26 RA patients as PMR. Conclusions The new 2012 EULAR/ACR clinical classification criteria for PMR can classify PMR patients with high sensitivity, however, its ability to discriminate PMR from other inflammatory conditions with shoulder pain, especially RA is poor. Other criteria sets, Jones or Nabunaga criteria, despite involvement of similar clinical parameters, perform better in discriminating PMR from RA and other inflammatory/noninflammatory articular diseases. Our results, therefore, suggest that in seronegative patients with bilateral shoulder pain and acute-phase response, differential diagnosis of PMR and RA may require imaging (as proposed also in the other version of the new criteria) or biomarker studies. Disclosure of Interest None declared

Background Currently 3 sets of criteria are available for inflammatory back pain (IBP) in spondyloarthritis: Calin, Berlin and the ASAS criteria. The performances of these criterias in differentiating IBP in psoriatic arthritis (PsA) with chronic low back pain (CLBP) is currently not known. Objectives The objective of this study was to assess performance of those 3 different criteria in a large multicentre PsA cohort. Methods PsART (Psoriatic Arthritis Registry of Turkey) is a prospective, multicentre, nationwide study in Turkey on patients with PsA. Patients are consecutively recruited to this registry, if they are diagnosed as PsA, regardless of any other disease characteristics. In this registry, CLBP was defined as back pain lasting for more than 3 months. All relevant data for IBP according to Calin, Berlin and ASAS criteria for IBP were collected. Results PsARTcohort included 746 PsA (35.3% male) patients. Overall, 170 of 746 (22.9%) of patients had CLBP. Median PsA duration was 47 (0-538) months. Patients with CLBP were more frequently males (44.4% vs 32.5%, p=0.004), more frequently had pitting (54.5% vs 41.3%, p=0.014) and less frequently had polyarthritis (26.3% vs 51.3%, p Conclusions Both Calin and Berlin criteria seem to be effective questionaires for evaluating IBP in PsA patients with CLBP. However, ASAS criteria did not perform well particularly in female patients. For this reason, the gender distribution may be an important aspect to consider when recruting patients in clinical trials as well as guiding physicians in clinical practice. Disclosure of Interest None declared

Calismanin amaci, ilkogretimde gorev yapan ogretmen ve yonetici ogretmenlerin tukenmislik duzeylerinin belirlenmesidir. Bunun yaninda calisma ile katilimcilarin tukenmislik duzeylerinin bazi sosyo-demografik degiskenlere gore farklilik gosterip gostermediginin belirlenmesi de hedeflenmektedir. Istanbul Kucukcekmece ilcesinde 40 ilkogretim kurumunda gorev yapan 160 ogretmen ve yonetici ogretmen arastirmanin calisma grubunu olusturmustur. Veri elde etme yontemi olarak Maslach Tukenmislik Envanteri Egitimci Formu kullanilmistir. Yapilan analizler neticesinde katilimci ogretmenlerin duygusal tukenme boyutunda yuksek, duyarsizlasma ve dusuk kisisel basari boyutlarinda ise, orta duzeyde tukenmislik yasadiklari belirlenmistir. Ayrica katilimcilarin tukenmislik duzeylerinin cinsiyet, yas, brans, cocuk durumu, gorev durumu, egitim durumu ve mesleki kidem degiskenlerine gore farklilastigi tespit edilmistir.